All In MedTech

Device Trial Radar · NCT02270931

A Prospective Longitudinal Breast Cancer Study

A Prospective Longitudinal Study of CA 15-3 as an Aid in Monitoring Recurrence or Progressive Disease in Patients With Breast Cancer

Last checked: Nov 20, 2026Latest source record: Aug 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

130

Planned (sponsor's estimate)

Start

May 2014

Primary completion

Jun 30, 2021

Study completion Jun 30, 2021

Sponsor

Lead sponsor
Fujirebio Diagnostics, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Oct 22, 2014

More device trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to obtain sufficient specimens and correlating clinical data from a well-controlled prospective clinical trial collecting longitudinal specimens from subjects diagnosed with any stage of breast cancer.

Conditions

  • Breast Cancer

Interventions

  • CA 15-3 AssayDevice

    Physicians use the CA 15-3 test result to manage their patients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Measure CA 15-3 in Breast Cancer PatientsTime frame: 3 years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Jane Skelton, MD

    Boca Raton, Florida

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.